A plant‐derived edible vaccine against hepatitis B virus

Kapusta, Józef; Modelska, A.; Figlerowicz, Magdalena; Pniewski, Tomasz; Letellier, Marie-Claude; Lisowa, O.; Yusibov, Vidadi; Koprowski, Hilary; Płucienniczak, Andrzej; Legocki, Andrzej B.

doi:10.1096/fasebj.13.13.1796

Cited by 331 publications

(192 citation statements)

References 11 publications

Supporting

Mentioning

186

Contrasting

Unclassified

Order By: Relevance

“…Plant-derived recombinant hepatitis-B surface antigen induced only a low level serum antibody response in a small human study, probably reflecting the low level of expression (1-5 ng g −1 fresh weight) in transgenic lettuce 27 . In spite of recent improvements in expression levels in potato with a view to clinical trials 31 , expression levels should be increased further for practical purposes.…”

Section: Plant-derived Biopharmaceuticals and Human Proteinsmentioning

confidence: 90%

“…Plant-expressed antigens have been shown to able to induce mucosal and serum immune responses when administered parenterally or orally to experimental animals and, in some test cases, they have offered protection against a subsequent pathogen challenge or challenge model 14,16,[19][20][21][22][23][24] . A few of these vaccine candidates have been successfully tested in clinical trials or, where appropriate, in commercial or native animal trials [25][26][27][28][29][30] . Thus, edible vaccines delivered in plant tissues or processed plant products show great potential for efficacy in target organisms.…”

Section: Edible Vaccinesmentioning

confidence: 99%

See 1 more Smart Citation

Medical molecular farming: production of antibodies, biopharmaceuticals and edible vaccines in plants

Daniell

Streatfield²,

Wycoff

2001

Trends in Plant Science

665

412

View full text Add to dashboard Cite

The use of plants for medicinal purposes dates back thousands of years but genetic engineering of plants to produce desired biopharmaceuticals is much more recent. As the demand for biopharmaceuticals is expected to increase, it would be wise to ensure that they will be available in significantly larger amounts, on a cost-effective basis. Currently, the cost of biopharmaceuticals limits their availability. Plant-derived biopharmaceuticals are cheap to produce and store, easy to scale up for mass production, and safer than those derived from animals. Here, we discuss recent developments in this field and possible environmental concerns.

show abstract

Section: Plant-derived Biopharmaceuticals and Human Proteinsmentioning

confidence: 90%

Section: Edible Vaccinesmentioning

confidence: 99%

Medical molecular farming: production of antibodies, biopharmaceuticals and edible vaccines in plants

Daniell

Streatfield²,

Wycoff

2001

Trends in Plant Science

665

412

View full text Add to dashboard Cite

show abstract

“…Hence, the approach has been shifted either in tubers or fruits or seeds of plants. Though such an approach yielded encouraging results, but there is concern regarding such vaccine in humans being less immunogenic (80).…”

Section: Edible Vaccinesmentioning

confidence: 99%

New dimensions in vaccinology: A new insight

Tomar

Chattree

Tripathi

et al. 2005

Indian J Clin Biochem

View full text Add to dashboard Cite

The development of vaccines to prevent infectious diseases has been one of the most important contributions of biomedical sciences. Increasing understanding in biochemistry, molecular biology, molecular genetics and related fields have provided an opportunity for the development of new generation vaccines that are based on rational design approaches. This is possible because of proper understanding of the microbial-genetics, biochemistry, host-pathogen interaction and recent developments in molecular immunology. Another important improvement made in the quality of vaccine production is the incorporation of immunomodulators or adjuvants with modified delivery vehicles viz liposomes, Iscoms and microspheres apart from alum being used as a gold standard. This article reviews the art of vaccination from Jenner period to present day context highlighting all the developments made at each stage of the vaccine development. Various cdteda have been discussed regarding the selection of epitopes that expand B & T cells, its linkage with other accessory cells of the immune system, means to overcome MHC linked immune unresponsiveness, enhanced antigen processing and presentations that specially induce either helper or cytotoxic or mucosal immune responses were critically discussed.

show abstract

“…For most licensed vaccines their indisputable safety with indubitable efficacy to elicit neutralizing antibodies has been achieved for human use [3]. Also the proportionate improvisation of technology has given different generations of recombinant and edible vaccines with Hepatitis B Virus as an example [4]. This expansion of knowledge and technology facilitate to unravel different aspects of the biological systems at the molecular level.…”

Section: Introductionmentioning

confidence: 99%

Conventional Vaccine to Prevent AIDS A Paradigm or A Paradox? A SWOT Analysis

Christdas¹

2016

HIV Curr Res

View full text Add to dashboard Cite

AIDS as a disease afflicts mankind for more than 3 decades. HIV, the causative is not yet checked with a prophylactic vaccine. The plausibility of the prevention by conventional prophylactic strategies based on Jenner's conventional method of inducing memory response is reviewed here. In order to find the right direction towards achieving this goal, a SWOT analysis is represented here with a Venn diagram. Our increasing awareness on the viral genome and the antiviral treatment with the sensitive diagnostic tools strengthen the efforts, while the viral nature privileges its replenishment by hampering the host immune memory. Though antiviral drugs promise a notable degree of control, they render selection pressure favoring viral escapism with perking quasispecies or circulating recombinant forms (CRF). Few historical clinical trials teach us to frame new opportunities for the conduct of such trials that assures safety. The knowledge has exponentially increased on the host immune response, human genetics, retrovirology, drug development, gene delivery system to understand that HIV is the only pathogen that had the greatest consumption of our time and resources. The technological advancements add to our strength. However, the virus with its biological features proves its intrinsic competency for survival. Though the antiviral therapy confers some hope, the resistant forms pose a threat to their continuation. It emphasizes the need for prevention and suggests novel, unconventional prophylaxis. Treatment as a means of prevention and the use of immunomodulators to decrease the disease progression can help us to win the belligerence against AIDS.

show abstract

A plant‐derived edible vaccine against hepatitis B virus

Cited by 331 publications

References 11 publications

Medical molecular farming: production of antibodies, biopharmaceuticals and edible vaccines in plants

Medical molecular farming: production of antibodies, biopharmaceuticals and edible vaccines in plants

New dimensions in vaccinology: A new insight

Conventional Vaccine to Prevent AIDS A Paradigm or A Paradox? A SWOT Analysis

Contact Info

Product

Resources

About